Dr. John Leonard presented key findings for the treatment of relapsed/refractory indolent non-Hodgkin’s lymphoma at the 2022 American Society of Hematology (ASH) Annual Meeting.
Presenting results from a 5-year follow-up phase 3 AUGMENT trial, Dr. Leonard and colleagues found that rituximab (Rituxan) plus lenalidomide (Revlimid) elicited superior progression-free survival for patients with relapsed/refractory indolent non-Hodgkin’s lymphoma.
The study involved 358 patients including a combination arm, using the rituximab plus lenalidomide, and a placebo arm.
“The updated results for OS are consistent with the improvement observed in PFS. These results, including OS data, further support the use of the regimen as a standard of care for patients with relapsed/refractory indolent non-Hodgkin lymphoma,” explained lead author of the study, Dr. Leonard, Chair of the Weill Department of Medicine and the Richard T. Silver Distinguished Professor of Hematology and Medical Oncology at Weill Cornell Medicine.
Reference: Leonard JP, Treny M, Offner F, et al. Five-year results and overall survival update from the phase 3 randomized study AUGMENT: lenalidomide plus rituximab versus rituximab plus placebo in patients with relapsed/refractory indolent non-Hodgkin lymphoma. Presented at the 2022 American Society of Hematology (ASH) Annual Meeting; December 10-13, 2022; New Orleans, LA. Abstract 230.